DrugPatentWatch Database Preview

Ucb Inc Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

UCB INC has forty approved drugs.

There are nineteen US patents protecting UCB INC drugs.

There are three hundred and forty-four patent family members on UCB INC drugs in forty-nine countries and forty-two supplementary protection certificates in thirteen countries.

International Patents:	344
US Patents:	19
Tradenames:	27
Ingredients:	22
NDAs:	40
Drug Master File Entries:	1
Patent Litigation for Ucb Inc:	See patent lawsuits for Ucb Inc

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	DIETHYLPROPION HYDROCHLORIDE	diethylpropion hydrochloride	TABLET;ORAL	085544-001	Approved Prior to Jan 1, 1982		DISCN	No	No		Start Trial				Start Trial
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-003	May 9, 2007		RX	Yes	No	9,925,150	Start Trial	Y			Start Trial
Ucb Inc	KEPPRA XR	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	022285-001	Sep 12, 2008	AB	RX	Yes	No	7,858,122	Start Trial	Y			Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	VIMPAT	lacosamide	SOLUTION;INTRAVENOUS	022254-001	Oct 28, 2008	5,654,301	Start Trial
Ucb Inc	FLUXID	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	021712-001	Sep 24, 2004	6,221,392	Start Trial
Ucb Inc	UNIRETIC	hydrochlorothiazide; moexipril hydrochloride	TABLET;ORAL	020729-001	Jun 27, 1997	4,344,949	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	1000 mg	➤ Subscribe	2007-01-24
➤ Subscribe	Tablets	50 mg, 100 mg, 150 mg, and 200 mg	➤ Subscribe	2012-10-29
➤ Subscribe	Extended-release Tablets	1000 mg	➤ Subscribe	2011-01-07
➤ Subscribe	Tablets	7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg	➤ Subscribe	2004-01-15
➤ Subscribe	Extended-release Transdermal Film	1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr	➤ Subscribe	2013-11-26
➤ Subscribe	Oral Solution	10 mg/mL	➤ Subscribe	2012-10-29
➤ Subscribe	Injection	10 mg/mL, 20 mL	➤ Subscribe	2016-06-30
➤ Subscribe	Orally Disintegrating Tablets	0.25 mg, 0.5 mg, 1 mg and 2 mg	➤ Subscribe	2005-12-27

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0503785	CA 2011 00026	Denmark	Start Trial	PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0454511	SPC/GB99/008	United Kingdom	Start Trial	PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
1033978	SZ 24/2006	Austria	Start Trial	PRODUCT NAME: ROTIGOTINE
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.